Russell Investments Group’s AMAG Pharmaceuticals AMAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-190,471
Closed -$1.79M 3291
2020
Q3
$1.79M Sell
190,471
-11,347
-6% -$108K ﹤0.01% 1752
2020
Q2
$1.54M Hold
201,818
﹤0.01% 1793
2020
Q1
$1.25M Buy
201,818
+31,751
+19% +$280K ﹤0.01% 1739
2019
Q4
$2.07M Buy
170,067
+68,367
+67% +$747K ﹤0.01% 1719
2019
Q3
$1.18M Buy
101,700
+10,900
+12% +$115K ﹤0.01% 1935
2019
Q2
$907K Buy
90,800
+43,600
+92% +$470K ﹤0.01% 2025
2019
Q1
$608K Buy
47,200
+24,400
+107% +$363K ﹤0.01% 2277
2018
Q4
$347K Sell
22,800
-513,409
-96% -$9.78M ﹤0.01% 2439
2018
Q3
$10.7M Sell
536,209
-634,123
-54% -$14.4M 0.02% 898
2018
Q2
$22.9M Buy
1,170,332
+415,741
+55% +$9.2M 0.05% 481
2018
Q1
$15.2M Buy
754,591
+148,113
+24% +$2.51M 0.03% 753
2017
Q4
$8.16M Sell
606,478
-38,704
-6% -$584K 0.01% 1086
2017
Q3
$11.9M Buy
645,182
+80,217
+14% +$1.5M 0.02% 859
2017
Q2
$10.4M Sell
564,965
-10,699
-2% -$212K 0.02% 903
2017
Q1
$13M Buy
575,664
+223,092
+63% +$5.34M 0.02% 740
2016
Q4
$12.4M Buy
+352,572
New +$10.5M 0.02% 749

Russell Investments Group's AMAG Position: Q4 2020 in Review

Russell Investments Group sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 190,471 shares — an estimated $1.79M sold.

Russell Investments Group first reported a position in AMAG in Q4 2016 and held it in 16 quarters. The position peaked at $22.9M in Q2 2018. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

  • Russell Investments Group reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Russell Investments Group sold 190,471 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1.79M.
  • Russell Investments Group first reported a position in AMAG Pharmaceuticals in Q4 2016 and held it in 16 quarters.
  • Russell Investments Group's AMAG Pharmaceuticals position peaked at $22.9M in Q2 2018.
  • 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on Russell Investments Group's 13F filing for Q4 2020, filed 8 Feb 2021.